Comparación del mapa T1, T2 y VEC por RMC en pacientes con miocardiopatía inflamatoria post-COVID-19 vs. daño miocárdico de etiología autoinmune.

Saved in:

Bibliographic Details
Title:	Comparación del mapa T1, T2 y VEC por RMC en pacientes con miocardiopatía inflamatoria post-COVID-19 vs. daño miocárdico de etiología autoinmune.
Alternate Title:	Comparing cardiac MRI ECV and T1 & T2 mapping in patients with post-COVID-19 inflamatory cardiomiopathy vs. autoimmune myocardial injury.
Authors:	Martínez-Juárez, David^1,2 www_david_@msn.com, Gómez-Monterrosas, Omar^3,4, Zamora-Rosales, Francisco⁵, Miró, Jordi^6,7, Cepeda-Ortiz, Daniel A.², Gamero-Aguilar, Jaredh Z.², Zamora-Medina, Jean², Mendoza-Aguilar, Rutilio², Sánchez-Guarneros, Karen H.⁵, Rosales-Medina, Moses D.²
Source:	Anales de Radiologia, Mexico. oct-dic2024, Vol. 23 Issue 4, p264-272. 9p.
Abstract (English):	Objective: Inflammatory cardiomyopathy is a disease associated with cardiac dysfunction and ventricular remodeling. Among the most recent diagnostic methods available, histologic characterization through cardiac magnetic resonance imaging (MRI) is used to identify inflammatory changes. Multiple studies have evaluated autoimmune mechanisms in myocardium damage following COVID-19, begging how feasible it is to differentiate and characterize lesions found in post-COVID-19 inflammatory cardiomyopathy. Method: Retrospective study comparing 29 MRI studies (12 diagnosed with post-COVID-19 inflammatory cardiomyopathy and 17 previously diagnosed with autoimmune cardiomyopathy, rheumatoid arthritis, scleroderma, or systemic lupus erythematosus), comparing the histologic characterization of T1, T2 mapping and extracellular volume (ECV) through cardiac MRI. Results: Post-COVID-19 inflammatory cardiomyopathy histologic characterization did not show significant differences compared to autoimmune myocardial lesions. T1 mapping 1109 ± 76 ms, T2 mapping 58 ± 6 ms, ECV 41 ± 9%. Myocardial lesions occurring from an autoimmune etiology showed: T1 mapping 1132 ± 122 ms, T2 mapping 61 ± 4 ms, and ECV 38 ± 8% (p > 0.05). Conclusion: T1-T2 mapping and ECV are similar among patients with post-COVID-19 inflammatory cardiomyopathy and myocardial damage secondary to autoimmune diseases, as there seem to exist similar pathologic mechanisms presenting in both groups, consistent with current literature regarding myocardial damage in SARS-CoV-2 infections. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Objetivo: La miocardiopatía inflamatoria (MCI) es una enfermedad asociada a disfunción cardiaca y remodelado ventricular. Actualmente entre los métodos diagnósticos se encuentra la caracterización tisular por resonancia magnética cardiaca (RMC), para identificar cambios inflamatorios. Múltiples investigaciones han evaluado mecanismos autoinmunes del daño miocárdico secundario a COVID-19, con la interrogante de si es posible diferenciar y caracterizar lesiones de MCI post-COVID-19. Método: Estudio retrospectivo y comparativo de 29 resonancias (12 pacientes fueron diagnosticados con MCI post-COVID-19 y 17 con daño miocárdico autoinmune), comparando la caracterización de los mapas T1, T2 y volumen extra celular (VEC) por RMC. Resultados: La caracterización tisular de pacientes con MCI post-COVID-19 no tuvo diferencias significativas respecto a pacientes con daño miocárdico de etiología autoinmune. MCI post-COVID-19: mapa T1 1,109 ms, mapa T2 58, VEC 41%. Daño miocárdico de etiología autoinmune: mapa T1 1,132 ms, mapa T2 61 ms y VEC 38 (p > 0.05). Conclusión: Los valores de mapa T1, T2 y VEC son similares entre pacientes con MCI post-COVID-19 y daño miocárdico por enfermedades autoinmunes, existiendo mecanismos similares de lesión miocárdica en ambos grupos, lo que es consistente con la literatura actual acerca de las vías de daño miocárdico por SARS-CoV-2. [ABSTRACT FROM AUTHOR]
	Copyright of Anales de Radiologia, Mexico is the property of Sociedad Mexicana de Radiologia e Imagen A.C. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Objective: Inflammatory cardiomyopathy is a disease associated with cardiac dysfunction and ventricular remodeling. Among the most recent diagnostic methods available, histologic characterization through cardiac magnetic resonance imaging (MRI) is used to identify inflammatory changes. Multiple studies have evaluated autoimmune mechanisms in myocardium damage following COVID-19, begging how feasible it is to differentiate and characterize lesions found in post-COVID-19 inflammatory cardiomyopathy. Method: Retrospective study comparing 29 MRI studies (12 diagnosed with post-COVID-19 inflammatory cardiomyopathy and 17 previously diagnosed with autoimmune cardiomyopathy, rheumatoid arthritis, scleroderma, or systemic lupus erythematosus), comparing the histologic characterization of T1, T2 mapping and extracellular volume (ECV) through cardiac MRI. Results: Post-COVID-19 inflammatory cardiomyopathy histologic characterization did not show significant differences compared to autoimmune myocardial lesions. T1 mapping 1109 ± 76 ms, T2 mapping 58 ± 6 ms, ECV 41 ± 9%. Myocardial lesions occurring from an autoimmune etiology showed: T1 mapping 1132 ± 122 ms, T2 mapping 61 ± 4 ms, and ECV 38 ± 8% (p > 0.05). Conclusion: T1-T2 mapping and ECV are similar among patients with post-COVID-19 inflammatory cardiomyopathy and myocardial damage secondary to autoimmune diseases, as there seem to exist similar pathologic mechanisms presenting in both groups, consistent with current literature regarding myocardial damage in SARS-CoV-2 infections. [ABSTRACT FROM AUTHOR]
ISSN:	16652118
DOI:	10.24875/ARM.24000009